Challenges in treating acute respiratory distress syndrome

Current Opinion in Critical Care

Volumn 2, Issue 1, 1996, Pages 73-78

  Repine, John E ^a   Abraham, Edward ^a  

^a Webb Waring Antioxidant Res I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1542422133     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-199602000-00011     Document Type: Article

References (25)

1. Bone RC: The adult respiratory distress syndrome: new trends. Med Times 1987, 115:33-40.
2. Repine JE: Scientific perspectives on adult respiratory distress syndrome. Lancet 1992, 339:466-469.
3. Flick MR: Mechanisms of acute lung injury: what have we learned from experimental animal models? Crit Care Clin 1986, 2:455-470.
4. Repine JE: Interleukin-1-mediated acute lung injury and tolerance to oxidative injury. Environ Health Perspect 1994, 102(suppl):75-78. Summarizes the potential dual-detremental-beneficial actions whereby IL-1 not only causes acute lung leak but also creates tolerance to oxidative injury.
5. Left JA, Baer JW, Bodman ME, Kirkman JM, Shanley PF, Patton LM, Guidot OM, Beehler CJ, McCord JM, Repine JE: Interleukin-1 α-induced neutrophil accumulation and oxygen metabolite mediated lung leak in rats. Am J Physiol 1994, 266:12-L8.
6. Siler TM, Swierkosz JE, Hyers TM, Fowler AA, Webster RO: Immunoreactive interleukin-1 in bronchoalveolar lavage fluid of high-risk patients and patients with the adult respiratory distress syndrome. Exp Lung Res 1989, 15:881-894.
7. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer J: High bronchoalveolar levels of tumor necrosis factor and its inhibitor, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992, 145:1016-1022.
8. Jacobs RF, Tabor DR, Burks AW, Campbell GD: Elevated interleukin-1 release by human alveolar macrophages during the adult respiratory distress syndrome. Am Rev Respir Dis 1989, 140:1686-1692.
9. Brown JM, White CW, Terada LS, Grosso MA, Shanley PF, Mulvin DW, Banerjee A, Whitmann GJ, Harken AH, Repine JE: Interleukin-1 pretreatment decreases ischemia-reperfusion injury. Proc Natl Acad Sci U S A 1990, 87:5026-5030.
10. Tsan MF, Lee CY, White JE: Interleukin-1 protects rats against oxygen toxicity. J Appl Physiol 1991, 71:688-697.
11. Leff JA, Wilke CP, Furman MJ, Bodman ME, Repine JE: Interleukin-1 protreatment prevents interleukin-1-induced lung leak in rats. Am J Physiol 1995, 268:L12-L16.
12. Leff JA, Parsons PE, Day CE, Taniguchi N, Jochum M, Fritz H, Moore FA, Moore EE, McCord JM, Repine JE: Serum antioxidants as predictors of the adult respiratory distress syndrome in septic patients. Lancet 1993, 341:777-780.
13. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, Kariman K, Higgins S, Bradley R, Metz CA, Harris TR, Brigham KL: High dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987, 317:1565-1570.
14. Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, Torky ME, Leeper KV: Fibroproliferative phase of ARDS: clinical findings and effects of corticosteroids. Chest 1991, 100:932-952.
15. 1 and survival in patients with the adult respiratory distress syndrome. Ann Surg 1986, 203:371-378.
16. 1 in patients with the adult respiratory distress syndrome. Chest 1989, 96:114-119.
17. 1 treatment decreases ventilation dependence in ARDS patients compared with placebo-treated control subjects.
18. Rosaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM: Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993, 328:399-405.
19. Yu M, Tomasa G: A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993, 21:1635-1642.
20. Hinson JR, Marini JJ: Principles of mechanical ventilator use in respiratory failure. Annu Rev Med 1992, 43:341-361.
21. Abraham E, Bursten S, Shenkar R, Allbee J, Tudor R, Woodson P, Guidot DM, Rice G, Singer JW, Repine JE: Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury following hemorrhage. J Exp Med 1995, 181:569-575. Treatment with a lisophosphatidic and pathway inhibitor decrease a lung leak and increased lung cytokine levels in mice subjected to hemmorrhage and resuscitation.
22. Schwartz MD, Repine JE, Abraham E: Xanthine oxidase-derived oxygen radicals increase lung cytokine expression in mice subjected to hemorrhagic shock. Am J Respir Cell Molec Biol 1995, 12:434-440. This paper links increases in lung cytokine expression in mice following hemmorrhage-resuscitation to xanthone oxidase (a well-known generator of oxygen radicals).
23. Bernard GR, Swindell BB, Meredith MJ, Carroll FE, Higgins SB: Glutathione (GSH) repletion by N-acetylcysteine in patients with the Adult Respiratory Distress Syndrome [abstract]. Am Rev Respir Dis 1989, 139:221A.
24. Bernard GR, Dupont W, Edens T, Higgins S, Jiang K, Morris P, Paz H, Russell J, Steinberg K, Stroud M, Swindell B, Wheeler AP, Wright P: Antioxidants in the acute respiratory distress syndrome (ARDS) [abstract]. Am J Respir Crit Care Med 1994, 149:A241. Treatment with glutathione enhancing agents N-acetylcysteine a procysteine decreases secondary organ dysfunction in ARDS patients.
25. Bernard GR, Artias A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R, and the Consensus Committee: Conference report: the American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824. Excellent concensus review regarding definitions, mechanisms, and treatment approaches for ARDS, including agents related to trial design.